Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Nova Scotia Health Authority
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00806234CT.gov Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Psychotic Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Metformin (this asset) | Nova Scotia Health Authority | Approved | BB · 64 |
| Olanzapine | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Risperidone | Northwell Health | P4 | BBB |
| Eukystol | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | P4 | BBB |
| Paliperidone | Consorcio Centro de Investigación Biomédica en Red (CIBER) | P4 | BBB |
| Asenapine | Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec | P4 | BBB |
| Simvastatin | Mclean Hospital | P4 | BBB |
| Sertraline | Northwell Health | P4 | BBB |
| Quetiapine | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
+42 more in the Psychotic Disorder cohort
Other indications for Metformin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prediabetes Syndrome | — | P4 | A · 81 |
| Gestational Diabetes | — | P4 | A · 81 |
| Diabetes Mellitus | — | P4 | A · 80 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- OlanzapineShanghai Jiao Tong University School of MedicineBBB
- RisperidoneNorthwell HealthBBB
- EukystolFundación Pública Andaluza para la gestión de la Investigación en SevillaBBB
- PaliperidoneConsorcio Centro de Investigación Biomédica en Red (CIBER)BBB
- AsenapineCentre de Recherche de l'Institut Universitaire en Santé Mentale de QuébecBBB
Citation
Floatz Terminal. Metformin in Psychotic Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/metformin-psychotic-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →